Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold

Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)

(2014) Koen Jansen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase

(2013) Sarah E. Poplawski et al.   JOURNAL OF MEDICINAL CHEMISTRY

Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold

(2013) Koen Jansen et al.   ACS Medicinal Chemistry Letters

Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity

(2012) Oxana Ryabtsova et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Rationale Behind Targeting Fibroblast Activation Protein-Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy

(2012) W. N. Brennen et al.   MOLECULAR CANCER THERAPEUTICS

Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes

(2011) Jon M. Sutton et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Structure–Activity Relationship Studies on Isoindoline Inhibitors of Dipeptidyl Peptidases 8 and 9 (DPP8, DPP9): Is DPP8-Selectivity an Attainable Goal?

(2011) Sebastiaan Van Goethem et al.   JOURNAL OF MEDICINAL CHEMISTRY

Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option

(2010) Kirstin Dienus et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Reply

(2010) Stefan Bauer et al.   ARTHRITIS AND RHEUMATISM

Expression and role of the cell surface protease seprase/fibroblast activation protein-α (FAP-α) in astroglial tumors

(2010) Rolf Mentlein et al.   BIOLOGICAL CHEMISTRY

(2S,4S)-1-[2-(1,1-Dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV

(2010) Teng-Kuang Yeh et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Substituted 4-Carboxymethylpyroglutamic Acid Diamides as Potent and Selective Inhibitors of Fibroblast Activation Protein

(2010) Ting-Yueh Tsai et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice

(2009) Angélica M. Santos et al.   JOURNAL OF CLINICAL INVESTIGATION

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

(2008) Bumsup Lee et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

(2008) L. Thomas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

On The Edge of Validation – Cancer Protease Fibroblast Activation Protein

(2008) Beni Wolf et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Fibroblast activation protein and chronic liver disease

(2007) Xin Maggie Wang   Frontiers in Bioscience-Landmark